Chuang, Tzu-Chao <br/><br/>
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.  [electronic resource] 

 -  Biochemical and biophysical research communications  Aug 2003 
 - 653-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0006-291X 
<br/><br/><label>Standard No.: </label>10.1016/s0006-291x(03)01235-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, Neoplasm<br/>Antineoplastic Agents--therapeutic use<br/>Apoptosis<br/>Carcinoma--drug therapy<br/>DNA Topoisomerases, Type II<br/>DNA-Binding Proteins<br/>Down-Regulation<br/>Doxorubicin--therapeutic use<br/>Drug Delivery Systems<br/>Drug Therapy, Combination<br/>Epstein-Barr Virus Nuclear Antigens--genetics<br/>Etoposide--therapeutic use<br/>Female<br/>G2 Phase<br/>Genetic Therapy<br/>Humans<br/>Kinetics<br/>Mitosis<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--therapeutic use<br/>Receptor, ErbB-2--metabolism<br/>Topoisomerase II Inhibitors<br/>Tumor Cells, Cultured